Fabrication of nanostructured lipid carriers ocugel for enhancing Loratadine used in treatment of COVID-19 related symptoms: statistical optimization, in-vitro, ex-vivo, and in-vivo studies evaluation

Rehab Abdelmonema Department of Industrial Pharmacy, College of Pharmaceutical Sciences and Drug Manufacturing, Misr University for Science and Technology, Giza, Egypt

Inas Essam Ibrahim Al-Samadia Department of Industrial Pharmacy, College of Pharmaceutical Sciences and Drug Manufacturing, Misr University for Science and Technology, Giza, Egypt

Rasha M. El Nasharb Department of Chemistry, Faculty of Science, Cairo University, Giza, Egypt

Bhaskara R. Jastic Department of Pharmaceutics and Medicinal Chemistry, Thomas J. Long School of Pharmacy and Healthy Science-Pacific University, Stockton, CA, USA

Mohamed A. El-Nabarawid Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University Giza, Giza, EgyptCorrespondence[email protected] [email protected]

Fabrication of nanostructured lipid carriers ocugel for enhancing Loratadine used in treatment of COVID-19 related symptoms: statistical optimization, in-vitro, ex-vivo, and in-vivo studies evaluation

Supplemental Material

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Fabrication of nanostructured lipid carriers ocugel for enhancing Loratadine used in treatment of COVID-19 related symptoms: statistical optimization, in-vitro, ex-vivo, and in-vivo studies evaluation

Supplemental Material

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date